Latest News

FDA approves Blueprint Medicines’ precision therapy for rare form of gastrointestinal cancer

Text FDA Approved appearing behind ripped brown paper.

The agency on Thursday approved Ayvakit (avapritinib) for gastrointestinal stromal tumor, or GIST, that harbors a PDGFRa exon 18 mutation. Still, identifying patients could be the biggest challenge, an analyst wrote.

Source link

Related posts

North Carolina Physicians’ Whistleblower Lawsuit Leads to Second Multi-Million-Dollar Recovery in Ground-Breaking Emergency Room Fraud Case


Researchers identify brain pathways of aversion


Syneron Candela wins FDA nod for Vbeam Prisma cosmetic laser


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy